Hôpital de la Croix-Rousse
18
2
3
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.6%
1 terminated/withdrawn out of 18 trials
90.9%
+4.3% vs industry average
11%
2 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection
Role: collaborator
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
Role: collaborator
Transplacental Neonatal Transfer of Lidocaine During Urgent Caesarean Delivery
Role: lead
Cot-side Suckometry and Oral Stimulation in Very Preterm Infants: A Pilot Study
Role: lead
Missed Opportunities to Pre-exposure Prophylaxis for HIV Infection on Person Newly Diagnosed With HIV
Role: collaborator
Functional Impact at 12 Months Post-op of Posterior Cruciate Ligament Conservation During Robotic-assisted Surgery (MAKO) for Total Knee Replacement.
Role: collaborator
Protocol of Diuretics Use in Congestive Therapy in Heart Failure
Role: collaborator
Cardiovascular Impairments and Obstructive Sleep Apnea Syndrome
Role: collaborator
Functional Evaluation After Maxillectomy and Scapular Free Flap Reconstruction
Role: lead
The CRESCENDO Program (inCRease Physical Exercise and Sport to Combat ENDOmetriosis)
Role: collaborator
Ventilator Settings on Patients With Acute Brain Injury
Role: collaborator
S-ICD French Cohort Study (HONEST)
Role: collaborator
Intrathecal Chloroprocaine for Lower Limb Arthroplasty
Role: lead
Nutritional Care and Head Growth in Preterm Infants
Role: lead
Body Composition at Discharge and Neurological Development at 2 Years in Very Preterm Infants (OPTIPREMA)
Role: lead
High Flow Nasal Cannula in Preterm Infants
Role: lead
Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci
Role: collaborator
Additional Protein Fortification in Extremely Low Birth Weight Infants
Role: lead
All 18 trials loaded